We have evaluated the feasibility of targeting metastatic vertebral lesions using metabolic PET and iPET with a view to treatment with SBRT in patients with metastatic CEA-expressing BC and MTC. The gene discussed is CEACAM5; the disease is medullary thyroid gland carcinoma.